Announcements Trials
Browse Landscape

Phase

Phase 3 69Phase 1 56Phase 2 49Phase 1/2 27Phase 4 2Phase NA 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Unresectable Non-small Cell Lung Cancer (NSCLC) 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × durvalumab × Clear all
NCT04078152 2024-12-20

WAVE

AstraZeneca

Phase 4 Completed
163 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04416633 2024-11-08

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

AstraZeneca

Phase 4 Completed
100 enrolled 11 charts
Thoracic

Unresectable Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡